Molecular Innovations Towards Theranostics of Aggressive Prostate Cancer
Abstract
In this project, we propose to develop a new drug delivery vehicle based on dendrimer nanotechnology for personalized medicine. This new class of nanoplatforms contains imaging probe and molecular medicine with a cancer-specific targeting capability which is able to target cancer cells, monitor drug delivery and tumor response to achieve a see and treat strategy as a new concept of molecular medicine. Specifically, One Partner PI s lab will make dendrimers bearing functional handles to conjugate with chelating agents provided by the Initiating PI s lab for PET imaging and therapeutic peptides provided by another Partner PI s lab for the treatment of aggressive prostate cancer. In the 1st year, the Initiating PI s lab has designed and synthesized the proposed bifunctional chelator scaffold system, CB-TE2A(tBu)2-N3 for the further construction of dendrimer-based theranostic agents for aggressive prostate cancer. In the meanwhile, the design concept has been extended to synthesize a bivalent imaging probe for quantitative PET imaging of PSMA expression in prostate cancer.
Document Details
- Document Type
- Technical Report
- Publication Date
- Sep 01, 2013
- Accession Number
- ADA590551
Entities
People
- Xiankai Sun
Organizations
- University of Texas at Dallas